Pemphigus Foliaceus

🧠 Standard of Care & Symptoms

Pemphigus Foliaceus (PF) is a rare, organ-specific autoimmune blistering skin disease. Unlike Pemphigus Vulgaris, it is characterized by superficial blistering and strictly spares the mucous membranes.

• Presentation: Key clinical features.
  • *Superficial Flaccid Blisters:* Tiny, fragile blisters that form in the upper layers of the skin. They rupture almost immediately, meaning intact blisters are rarely seen on clinical examination.
  • *Seborrheic Distribution:* Lesions typically start on the face, scalp, and upper torso (areas with high density of sebaceous glands) as scaly, crusted, erythematous plaques.
  • *Raw Erosions:* Ruptured blisters leave painful, raw, oozing, and crusted areas that resemble superficial burns. These can become widespread and lead to exfoliative erythroderma in severe cases.
  • *Nikolsky Sign:* Applying lateral pressure to normal-appearing skin adjacent to a lesion causes the epidermis to slide off easily, confirming active superficial intraepidermal cleavage.

🧬 Diagnostics & Pathophysiology

Diagnosis is established via histopathological analysis, direct immunofluorescence of a skin biopsy, and circulating antibody serology.

• Diagnostic Markers: Key criteria.
  • Skin Biopsy: Histology shows subcorneal intraepidermal clefting (splitting of the skin layers) and **acantholysis** (loss of cell-to-cell adhesion) specifically in the granular layer of the epidermis.
  • Direct Immunofluorescence (DIF): Reveals deposition of IgG autoantibodies and C3 in a net-like or "chicken-wire" pattern restricted to the superficial/upper layers of the epidermis.
  • Dsg1 ELISA: Serum testing detects high titers of circulating anti-Desmoglein 1 autoantibodies, which correlate with disease severity. Anti-Desmoglein 3 titers remain negative.

Pathophysiology of Desmoglein 1 Disruption

The clinical presentation of Pemphigus Foliaceus is driven by the autoantibody targeting of desmosomal cadherins:

• Targeting Desmoglein 1 (Dsg1): Pathogenic IgG autoantibodies target **Desmoglein 1**, a key cell-adhesion glycoprotein that anchors keratinocytes together in the superficial layers of the epidermis.
• Mucosal Sparing: Dsg1 is highly expressed in the skin but not in mucosal tissues, where Desmoglein 3 (Dsg3) is dominant. Because Dsg3 is unaffected in PF, the mucous membranes remain entirely spared from blistering.
• Subcorneal Acantholysis: Autoantibody binding blocks Dsg1-mediated cell adhesion and triggers cell signaling cascades that lead to desmosome internalization. The loss of adhesion (**acantholysis**) occurs in the superficial granular layer, causing thin-roofed, fragile blisters.

💊 Therapeutic Interventions & Biologics

Treatment aims to suppress autoantibody production and promote skin healing, transitioning from systemic steroids to targeted biologics.

First-Line Pharmacotherapy

• Systemic Corticosteroids: High-dose oral prednisone (0.5 to 1.0 mg/kg daily) is initiated to achieve rapid control of blister formation. Once control is established, steroids are slowly tapered.
• Rituximab: A humanized monoclonal antibody targeting **CD20+ B-cells**. Deployed early as a first-line steroid-sparing biologic, Rituximab depletes the autoantibody-producing B-cell populations, enabling sustained clinical remission and minimizing steroid toxicity.

Steroid-Sparing Immunosuppressants

• Mycophenolate Mofetil (MMF) & Azathioprine: Used as adjuvant therapies to maintain remission during and after the corticosteroid taper.
• Topical Therapy & Wound Management: High-potency topical corticosteroids for localized lesions. Use of non-adherent dressings, protective emollients, and antiseptic washes is recommended to prevent secondary bacterial infections.

🔬 Active Clinical Trials

Clinical trials are currently investigating novel oral BTK inhibitors, neonatal Fc receptor (FcRn) blockers, and engineered cell therapies.

🗺️ Next Steps After Diagnosis

If you have recently been diagnosed with Pemphigus Foliaceus, establish these clinical care pathways:

1. Confirm ELISA Serology: Review your anti-Dsg1 and anti-Dsg3 antibody titers with a dermatologist specializing in immunodermatology.
2. Establish First-Line Biologic Plan: Discuss the timing of Rituximab infusions to minimize long-term reliance on high-dose oral corticosteroids.
3. Optimize Skin Barrier Protection: Implement gentle skin hygiene, avoid tight clothing that causes friction, and use thick, protective moisturizers.
4. Implement Wound Care Protocol: Work with a wound care nurse to identify non-adherent dressings for raw erosions to promote epithelialization.

❓ Patient FAQ

Q: What is the difference between Pemphigus Foliaceus and Pemphigus Vulgaris?
A: In **Pemphigus Foliaceus**, autoantibodies only target Desmoglein 1 (Dsg1), which is present in the superficial skin. Therefore, blistering is very shallow and the mouth/mucous membranes are completely spared. In **Pemphigus Vulgaris**, autoantibodies target Desmoglein 3 (Dsg3) (with or without Dsg1), leading to deeper, highly painful blisters that frequently involve the mouth and throat.

Q: Is Pemphigus Foliaceus contagious or hereditary?
A: No. It is an autoimmune condition, meaning it is caused by the immune system mistakenly attacking the body's own proteins. It cannot be caught from someone else and is not directly passed down through families (though a genetic predisposition to autoimmunity in general may exist).